AXSM רווח למניה בשנים עשר החודשים האחרונים Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) is building on the success of Auvelity and Sunosi by expanding the list of indications for the treatment of migraine and Alzheimer's disease. Net income per share over the last 12 months confirms the resilience of the model, where the parameter value reaches -3.07. Returns are based on partnerships with research organizations, while the active penetration of new sales markets ensures a steady influx of patients.

Investors utilize this indicator as the primary marker of return on equity, assessing the portion of net income attributable to a single common share. The calculation logic for the current EPS TTM level is based on total annual income, which for Axsome Therapeutics (AXSM) confirms the effectiveness of commercializing migraine and depression treatments, creating an internal growth driver independent of macroeconomic fluctuations.